N-methyl-N-tosylpropylamine | 57186-69-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-methyl-N-tosylpropylamine
• 英文别名: Methyl-n-propylamintosylat；Toluol-sulfomethyl-propylamid；N-methyl-N-propyl-4-methylbenzenesulfonamide；N-methyl-N-propyl-toluene-4-sulfonamide；N-Methyl-N-propyl-toluol-4-sulfonamid；N,4-dimethyl-N-propylbenzenesulfonamide
• CAS: 57186-69-3
• 化学式: C₁₁H₁₇NO₂S
• mdl: MFCD18974077
• 分子量: 227.327
• InChiKey: QFEYZSVDSWSXEM-UHFFFAOYSA-N

物化性质

• 熔点：
  40 °C
• 沸点：
  328.7±35.0 °C(Predicted)
• 密度：
  1.112±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-methyl-N-tosylpropylamine 在 盐酸 作用下， 生成 N-甲基正丙胺
  参考文献：
  名称：

  Wassermann, Arzneimittel-Forschung/Drug Research, 1972, vol. 22, # 11, p. 1993 - 1995

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 sodium ethanolate 作用下， 生成 N-methyl-N-tosylpropylamine
  参考文献：
  名称：

  The Addition of N-Haloamides to Olefins

  摘要：

  DOI：

  10.1021/ja01267a057

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS
  申请人：HADIDA RUAH SARA S.

  公开号：US20090143381A1

  公开（公告）日：2009-06-04

  Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药用可接受的组合物可用作ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节蛋白（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。
• Titanium‐Catalyzed Hydroaminoalkylation of Ethylene
  作者：Michael Rosien、Iris Töben、Marc Schmidtmann、Rüdiger Beckhaus、Sven Doye

  DOI：10.1002/chem.201904502

  日期：2020.2.17

  The first examples of titanium-catalyzed hydroaminoalkylation reactions of ethylene with secondary amines are presented. The reactions can be achieved with various titanium catalysts and they do not require the use of high pressure equipment. In addition, the first solid-state structure of a titanapyrrolidine that is formed by insertion of an alkene into the Ti-C bond of a titanaaziridine is reported

  提出了钛与乙烯和仲胺的钛催化的加氢氨基烷基化反应的第一个实例。该反应可以用各种钛催化剂实现，并且它们不需要使用高压设备。另外，报道了通过将烯烃插入到钛氮丙啶的Ti-C键中而形成的钛吡咯烷的第一固态结构。
• Modulators of ATP-binding cassette transporters
  申请人：Ruah Sara S. Hadida

  公开号：US20080113985A1

  公开（公告）日：2008-05-15

  Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药学上可接受的组合物，可用作ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节因子（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。